Mineralys Therapeutics announced on April 23, 2025, that detailed results from its pivotal Phase 2 Advance-HTN trial were published in The New England Journal of Medicine (NEJM). This publication is a significant milestone, underscoring the strength of the clinical data for lorundrostat.
The NEJM article highlighted that lorundrostat 50 mg demonstrated a 15.4 mmHg absolute reduction and a 7.9 mmHg placebo-adjusted reduction (p=0.001) in 24-hour ambulatory blood pressure at week 12. The drug showed consistent efficacy across various patient demographics, including men and women, and white and black patients.
The publication reinforces the critical role of dysregulated aldosterone in hypertension and the potential of lorundrostat to address unmet medical needs in patients with uncontrolled or treatment-resistant disease. A favorable safety and tolerability profile, with modest changes in potassium, sodium, and eGFR, was also noted.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.